Biosens Bioelectron:苏州医工所在房颤抗凝快速检测方面取得进展

2017-12-27 张威 中科院苏州医工所

近年来,由于高盐高脂的饮食习惯和亚健康生活方式,很容易导致高血压、糖尿病、冠心病和房颤等疾病的发生。房颤是最常见的持续心律失常现象,是指心肌失去了正常舒缩活动,代之以快速而不协调的微弱蠕动,致使心房失去了正常的有效收缩。患者的心房由于过快且无规律的收缩,导致血液不能完全泵出心房,因而在心房内淤滞导致血凝块的形成。

近年来,由于高盐高脂的饮食习惯和亚健康生活方式,很容易导致高血压糖尿病、冠心病和房颤等疾病的发生。房颤是最常见的持续心律失常现象,是指心肌失去了正常舒缩活动,代之以快速而不协调的微弱蠕动,致使心房失去了正常的有效收缩。患者的心房由于过快且无规律的收缩,导致血液不能完全泵出心房,因而在心房内淤滞导致血凝块的形成。如果没有适当的抗凝治疗,一旦这些血凝块脱落并流经脑部细长血管时,极易引起血栓栓塞性并发症,进而引发脑卒中,危及生命。因此在临床上,房颤病人需要进行长期的口服抗凝剂治疗。凝血酶原时间(PT)和活化部分凝血活酶时间(APTT)是血栓、房颤及植入术后患者接受长期抗凝治疗时需定期检测的重要参数。但现有检测设备几乎都依赖于检验科的大型全自动仪器,新型的POCT型仪器售价昂贵,核心技术基本也被国外公司垄断。

近日,苏州医工所周连群团队张威博士基于高灵敏压电薄膜传感技术设计并加工了一种高稳定性、可重复的Parylene-C材料修饰的QCM器件(P-QCM),搭建了部分活化凝血时间(APTT)快速检测系统,有效解决了房颤抗凝快速检测问题。P-QCM芯片的制备和器件形貌及电学特性表征结果表明,P-QCM可以稳定吸附凝血终产物纤维蛋白并提高传感器的灵敏度和稳定性。与光学标准仪器及临床检验科希森美康(SYSMEX CS2000i)设备比较,对多份临床样本进行比对检测,APTT时间检测结果变异系数CV值为1.24%,10个不同样本的P-QCM和希森美康仪器比对结果相关系数为0.983。以上结果表明 P-QCM具备成为小型化凝血传感器核心部件的优越性能,为进一步开发便携式心脑血管抗凝检测平台提供了关键技术。相关研究结果已发表在Biosensors and Bioelectronics上。

本工作得到中国科学院、科技部、国家自然科学基金、江苏省自然科学基金、江苏省产业技术研究院的项目资助。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1694818, encodeId=cb14169481853, content=<a href='/topic/show?id=a7385426313' target=_blank style='color:#2F92EE;'>#房颤抗凝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54263, encryptionId=a7385426313, topicName=房颤抗凝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8df129768056, createdName=xiongke020, createdTime=Wed Apr 25 11:03:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917854, encodeId=fa5c191e85417, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 20 06:03:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785158, encodeId=bbae1e85158fa, content=<a href='/topic/show?id=fa9c66656d' target=_blank style='color:#2F92EE;'>#electron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6665, encryptionId=fa9c66656d, topicName=electron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Thu Jan 04 10:03:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281566, encodeId=b0ec281566e0, content=看看了解一下.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Jan 24 12:41:03 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1694818, encodeId=cb14169481853, content=<a href='/topic/show?id=a7385426313' target=_blank style='color:#2F92EE;'>#房颤抗凝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54263, encryptionId=a7385426313, topicName=房颤抗凝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8df129768056, createdName=xiongke020, createdTime=Wed Apr 25 11:03:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917854, encodeId=fa5c191e85417, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 20 06:03:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785158, encodeId=bbae1e85158fa, content=<a href='/topic/show?id=fa9c66656d' target=_blank style='color:#2F92EE;'>#electron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6665, encryptionId=fa9c66656d, topicName=electron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Thu Jan 04 10:03:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281566, encodeId=b0ec281566e0, content=看看了解一下.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Jan 24 12:41:03 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-11-20 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1694818, encodeId=cb14169481853, content=<a href='/topic/show?id=a7385426313' target=_blank style='color:#2F92EE;'>#房颤抗凝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54263, encryptionId=a7385426313, topicName=房颤抗凝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8df129768056, createdName=xiongke020, createdTime=Wed Apr 25 11:03:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917854, encodeId=fa5c191e85417, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 20 06:03:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785158, encodeId=bbae1e85158fa, content=<a href='/topic/show?id=fa9c66656d' target=_blank style='color:#2F92EE;'>#electron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6665, encryptionId=fa9c66656d, topicName=electron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Thu Jan 04 10:03:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281566, encodeId=b0ec281566e0, content=看看了解一下.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Jan 24 12:41:03 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1694818, encodeId=cb14169481853, content=<a href='/topic/show?id=a7385426313' target=_blank style='color:#2F92EE;'>#房颤抗凝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54263, encryptionId=a7385426313, topicName=房颤抗凝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8df129768056, createdName=xiongke020, createdTime=Wed Apr 25 11:03:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917854, encodeId=fa5c191e85417, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 20 06:03:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785158, encodeId=bbae1e85158fa, content=<a href='/topic/show?id=fa9c66656d' target=_blank style='color:#2F92EE;'>#electron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6665, encryptionId=fa9c66656d, topicName=electron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Thu Jan 04 10:03:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281566, encodeId=b0ec281566e0, content=看看了解一下.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Wed Jan 24 12:41:03 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-01-24 xiaotaiyang1

    看看了解一下.谢谢分享

    0

相关资讯

不要遇到房颤就药物复律

患者老年女性,80岁,因“反复胸闷憋喘1周,加重伴不能平卧1天”入急诊科,急诊心电图示房颤伴快速性心室率。查体:Bp 177/ 120mmHg。

Int J Cardiol:房颤患者外周和冠状动脉病变与心血管事件的关系!

由此可见,伴有CAD的无症状PAD患者具有较高的风险发生CVEs,当存在PAD与CAD相关的血管疾病负担时风险渐进性增加。

Am J Kidney Dis:合并CKD-5D的房颤患者:口服抗凝药预防卒中效果如何?

2017年12月,发表在《Am J Kidney Dis》上的一项综述,对口服抗凝药用于合并5D期慢性肾病(CKD-5D)的房颤(AF)患者卒中预防的风险和获益的迫切性进行了阐述。

JACC:依普利酮可减少房颤负担,但不影响心房电重构

醛固酮抑制剂依普利酮(EPL)可以减少收缩型心衰患者房颤的发病风险,然而,其具体机制尚未阐明。本研究将34只房性心动过速的山羊(13 ± 1周)随机分成每日口服EPL组(n=19)和糖片对照组(n=14),主要终点事件是连续七天的房颤(n=29)或持续23周的心动过速(n=5)。结果显示,EPL可以明显减少房颤发展过程中左房的扩张率。与对照组相比,口服EPL的山羊的心房平滑肌肌动蛋白、Ⅲ型胶原表达

Eur J Clin Pharmacol:快来看呀!房颤住院患者更具代表性的直接口服抗凝药试验

2017年发表在《Eur J Clin Pharmacol》的一项由澳大利亚科学家进行的横断面研究,考察了房颤(AF)住院患者中直接口服抗凝药(DOACs)临床试验的代表性。

张萍教授谈:射频消融术后抗心律失常药物的使用

心律失常是一类疾病的统称,指心脏的正常节律发生异常改变,如心率加快或减慢、节律不规整,也包括起源部位异常和传导异常等。临床常见心律失常有心动过缓、频发房早和室早、心动过速、房颤等。